Advancement of Phase III Clinical Trials: Implement multicenter randomized controlled trials (e.g., inetetamab + SOX vs. trastuzumab + SOX) with: Primary endpoint: Overall survival (OS); Secondary assessments: Quality of life (QoL) metrics and cost-effectiveness analyses; Prespecified subgroup analyses: PD-L1 expression, HER2 copy number variation, and tumor mutational burden (TMB) to identify beneficiary populations. This evidence concerns the gene ERBB2 and neoplasm.